In a Prediabetic Model,Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia |
| |
| Authors: | Martina Hü ttl,Irena Markova,Denisa Miklankova,Iveta Zapletalova,Martin Poruba,Martin Haluzik,Ivana Vaně č kova,Hana Malinska |
| |
| Affiliation: | 1.Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic; (M.H.); (I.M.); (D.M.);2.Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic; (I.Z.); (M.P.);3.Diabetes Centre, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic;4.Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, 14220 Prague, Czech Republic; |
| |
| Abstract: | |
| |
| Keywords: | SGLT-2 inhibitors empagliflozin fatty liver lipid metabolism cytochrome P450 fetuin-A oxidative stress |
|
|
